{
  "ticker": "BIT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973889",
  "id": "02973889",
  "pages": 7,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1319",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8765zlvtzw2.pdf",
  "summary": "### **Summary of Material Information**  \n\n#### **Capital Raising Announcement**  \n- **Entitlement Issue**: Raised **$1.27M** (before costs; partially underwritten by Mahe Capital for **$750k**) via renounceable rights offer (completed **8 Apr 2025**).  \n\n#### **Quarterly Report (Appendix 4C)**  \n- **Cash Balance**: **$932k** (end quarter).  \n- **Net Operating Cash Flow**: **-$599k** (quarter), **-$565k** (YTD).  \n- **R&D Spend**: **$139k** (quarter), **$758k** (YTD).  \n- **Funding Runway**: **1.56 quarters** (based on current cash and burn rate).  \n- **Subsequent R&D Incentive**: Expected **$200k** in FY26 (first half).  \n\n#### **Operational Highlights**  \n- **HBV Drug Progress**: Completed **Phase 1 animal safety study** (no toxicity observed); advancing to efficacy testing in two HBV mouse models.  \n- **Commercialization**: Ongoing partner discussions via **C14 Consulting** (including BIO2025 meetings).  \n\n#### **Other Material Updates**  \n- **Board Change**: Appointment of **Michael Medway** (Non-Executive Director).  \n\n*No material information omitted; all non-essential details excluded per instructions.*",
  "usage": {
    "prompt_tokens": 3860,
    "completion_tokens": 290,
    "total_tokens": 4150,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T03:48:09.595885"
}